{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:32:21Z","timestamp":1793946741188,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.diabres.2026.113244","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:43:45Z","timestamp":1775493825000},"page":"113244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Oral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian study"],"prefix":"10.1016","volume":"236","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7462-7792","authenticated-orcid":false,"given":"Andrea","family":"Giaccari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Borroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5542-5941","authenticated-orcid":false,"given":"Marco","family":"Dauriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gioia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paris","family":"Baptiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusi","family":"Lastoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthana","family":"Udupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Barbagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113244_b0005","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison with Placebo in patients with Type 2 Diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113244_b0010","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral Semaglutide Versus Empagliflozin in patients with Type 2 Diabetes Uncontrolled on Metformin: the PIONEER 2 Trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113244_b0015","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in adults with Type 2 Diabetes Uncontrolled with Metformin Alone or with Sulfonylurea: the PIONEER 3 Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2026.113244_b0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113244_b0025","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113244_b0030","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113244_b0035","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113244_b0040","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo added to Insulin with or without Metformin in patients with Type 2 Diabetes: the PIONEER 8 Trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113244_b0045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113244_b0050","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial","volume":"8","author":"Yabe","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2026.113244_b0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001649","article-title":"Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial","volume":"8","author":"Buse","year":"2020","journal-title":"BMJ Open Diab Res Care"},{"key":"10.1016\/j.diabres.2026.113244_b0060","unstructured":"Evidence-Based Medicine - StatPearls - NCBI Bookshelf. Accessed July 22, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470182\/."},{"issue":"65","key":"10.1016\/j.diabres.2026.113244_b0065","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"2022","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2026.113244_b0070","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00592-023-02107-x","article-title":"2023 update on italian guidelines for the treatment of type 2 diabetes","volume":"60","author":"Mannucci","year":"2023","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabres.2026.113244_b0075","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00592-022-01857-4","article-title":"Italian guidelines for the treatment of type 2 diabetes","volume":"59","author":"Mannucci","year":"2022","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabres.2026.113244_b0080","year":"2022","journal-title":"Published online"},{"key":"10.1016\/j.diabres.2026.113244_b0085","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2337\/diacare.28.3.626","article-title":"Assessing Psychosocial Distress in Diabetes","volume":"28","author":"Polonsky","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113244_b0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.appet.2013.08.010","article-title":"Italian version of the Dutch Eating Behavior Questionnaire. Psychometric proprieties and measurement invariance across sex, BMI-status and age","volume":"71","author":"Dakanalis","year":"2013","journal-title":"Appetite"},{"key":"10.1016\/j.diabres.2026.113244_b0095","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/1098-108X(198602)5:2<295::AID-EAT2260050209>3.0.CO;2-T","article-title":"The Dutch Eating Behavior Questionnaire (DEBQ) for assessment of restrained, emotional, and external eating behavior","volume":"5","author":"Van Strien","year":"1986","journal-title":"Int J Eat Disord"},{"key":"10.1016\/j.diabres.2026.113244_b0100","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2337\/dc11-1572","article-title":"When is Diabetes Distress Clinically Meaningful?","volume":"35","author":"Fisher","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113244_b0105","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s40618-024-02309-2","article-title":"Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study","volume":"47","author":"Bonora","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.diabres.2026.113244_b0110","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.3390\/jcm12186052","article-title":"Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-on Therapy) in Type 2 Diabetes","volume":"12","author":"Candido","year":"2023","journal-title":"JCM"},{"key":"10.1016\/j.diabres.2026.113244_b0115","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s13300-024-01614-6","article-title":"PIONEER REAL Sweden: a Multicentre, prospective, Real-World Observational Study of Oral Semaglutide Use in adults with Type 2 Diabetes in Swedish Clinical Practice","volume":"15","author":"Catrina","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2026.113244_b0120","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/dom.15493","article-title":"Use of once\u2010daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: a multicentre, prospective real\u2010world study (PIONEER REAL Canada)","volume":"26","author":"Jain","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113244_b0125","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s13300-023-01525-y","article-title":"Real-World use of Oral Semaglutide in adults with Type 2 Diabetes: the PIONEER REAL Switzerland Multicentre, prospective","volume":"15","author":"Kick","year":"2024","journal-title":"Observational Study Diabetes Ther"},{"key":"10.1016\/j.diabres.2026.113244_b0130","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s13300-024-01588-5","article-title":"Real-World use of Oral Semaglutide in adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, prospective","volume":"15","author":"Van Houtum","year":"2024","journal-title":"Observational Study Diabetes Ther"},{"key":"10.1016\/j.diabres.2026.113244_b0135","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1007\/s12325-024-02973-z","article-title":"PIONEER REAL UK: a Multi-Centre, prospective, Real-World Study of Once-Daily Oral Semaglutide Use in adults with Type 2 Diabetes","volume":"41","author":"Saravanan","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabres.2026.113244_b0140","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/jdi.14291","article-title":"PIONEER REAL Japan: Primary results from a multicenter, prospective, real\u2010world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice","volume":"15","author":"Yabe","year":"2024","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2026.113244_b0145","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/jdi.14219","article-title":"PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real\u2010world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan","volume":"15","author":"Suzuki","year":"2024","journal-title":"J of Diabetes Invest"},{"key":"10.1016\/j.diabres.2026.113244_b0150","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jdiacomp.2015.11.010","article-title":"Depressive symptoms, serious psychological distress, diabetes distress and cardiovascular risk factor control in patients with type 2 diabetes","volume":"30","author":"Winchester","year":"2016","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2026.113244_b0155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11606-018-4705-2","article-title":"The Importance of addressing Depression and Diabetes Distress in adults with Type 2 Diabetes","volume":"34","author":"Owens-Gary","year":"2019","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.diabres.2026.113244_b0160","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2337\/dc06-1614","article-title":"Clinical Depression Versus Distress among patients with Type 2 Diabetes","volume":"30","author":"Fisher","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113244_b0165","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1464-5491.2008.02533.x","article-title":"A longitudinal study of affective and anxiety disorders, depressive affect and diabetes distress in adults with Type 2 diabetes","volume":"25","author":"Fisher","year":"2008","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2026.113244_b0170","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.pec.2016.03.020","article-title":"Biobehavioral determinants of glycemic control in type 2 diabetes: a systematic review and meta-analysis","volume":"99","author":"Brown","year":"2016","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.diabres.2026.113244_b0175","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once\u2010weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113244_b0180","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 4. Lifestyle Management. Diabetes Care 2017;40(Supplement_1):S33-S43. doi:10.2337\/dc17-S007.","DOI":"10.2337\/dc17-S007"},{"key":"10.1016\/j.diabres.2026.113244_b0185","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.2337\/dc16-2053","article-title":"Psychosocial Care for People with Diabetes: a Position Statement of the American Diabetes Association","volume":"39","author":"Young-Hyman","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2026.113244_b0190","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1093\/eurjpc\/zwaa073","article-title":"Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC\/EASD: data from a large Mediterranean population","volume":"28","author":"Cebri\u00e1n-Cuenca","year":"2022","journal-title":"Eur J Prev Cardiol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726001634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:59:02Z","timestamp":1793944742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726001634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"alternative-id":["S0168822726001634"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113244","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113244","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113244"}}